Polsinelli provides public policy counsel to health care clients that is grounded in its deep understanding of the health care industry as well as the regulatory and statutory framework that continues to significantly affect the industry on the whole.

Supported by highly experienced senior policy advisers, our public policy team partners with our national health care practice to provide strong advocacy to health care clients at the state and federal levels.

With a focus on advancing clients’ legislative and policy objectives, our firm has become intimately familiar with all aspects of the federal reform law including implementation at the state level. We also have experience working with the Centers for Medicare and Medicaid Services and Health and Human Services on the interpretation and amendment of a wide variety of health care regulations. Our public policy attorneys also have first-hand knowledge of the inner workings of the various state and federal agencies that impact the health care industry on a daily basis. Our experience includes:

  • Forming coalitions of provider groups to leverage interests and effectuate regulatory change or to challenge regulations and statutes
  • Lobbying for revised interpretations of regulations adversely affecting our health care clients
  • Lobbying for coverage decisions under Medicare
  • Drafting and submitting grant applications on behalf of our health care clients

Whether at the national level working with executive agencies or the White House or at the local level collaborating with city, county and state governments, our team focuses on maintaining a full understanding of the legislative and regulatory environment while also maintaining relationships with key decision makers that can be integral to achieving a health care organization’s objectives.

Related Capabilities
Publications
House Panel Moves to Block CMS’s AI-Driven Prior Authorization Program: What the WISeR Rider Could Mean for Providers
Key Takeaways The House Appropriations Committee approved a rider June 9 that would block FY 2027 funding for CMS’s WISeR model. Unless the rider becomes law, however, the AI-driven prior authorization program will remain active in the six states where it currently operates. The rider could halt WISeR for FY 2027, but several legislative paths remain in play. Senate negotiations, a conference agreement or a continuing resolution could allow the program to continue, meaning providers should assume WISeR requirements remain in effect for now. Providers should continue documenting WISeR non-affirmations, appeals, outcomes and operational burdens. Those records may prove valuable for compliance efforts, litigation strategy and legislative advocacy as scrutiny of the program continues. On June 9, 2026, the House Appropriations Committee approved a
Read More
Beyond the Pump: The Iran War’s Adverse Impact on U.S. Health Care
Key Takeaways The closure of the Strait of Hormuz following the U.S.-Iran conflict is disrupting global health care supply chains and increasing costs for critical medical products. Shortages and delays are already affecting pharmaceuticals, MRI-related helium supplies and cold-chain products. The disruptions create operational and financial pressure for health care providers that depend on imported drugs, medical equipment and time-sensitive supplies. Rising freight, fuel and insurance costs are contributing to higher prices and longer lead times across multiple product categories. Health care organizations should closely monitor supply availability, transportation delays and pricing volatility tied to the ongoing conflict and shipping restrictions. Providers may need to evaluate inventory levels, supplier diversification and contingency planning for critical medical inputs. Since the beginning of the United States’
Read More